Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability […]Read More
Earlier this week one of our portfolio companies, Genalyte, Inc., announced the release of a groundbreaking diagnostic system for early detection of Type 1 diabetes. This is of special significance to me as the young daughter of a good friend almost died due to undiagnosed Type 1 Diabetes – she was discovered by her parents […]Read More
I’m excited that we have recently added a new portfolio company Genalyte to the Claremont Creek digital healthcare family. I’ll be joining the Board, and I am looking forward to working with founder and CEO Cary Gunn and the Genalyte team. Genalyte is a developer and manufacturer of advanced biomarker detection technology strategically located right […]Read More
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.